Antifungal drug resistance: Does it matter?

International Journal of Infectious Diseases

Volumn 6, Issue SUPPL. 1, 2002, Pages

  Rogers, Thomas R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; TERBINAFINE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; CANDIDA ALBICANS; CLINICAL TRIAL; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESPONSE; EPIDEMIOLOGICAL DATA; FUNGAL STRAIN; FUNGAL VIRULENCE; HOST RESISTANCE; HUMAN; INCIDENCE; MUTAGENESIS; MYCOSIS; NEPHROTOXICITY; PHARMACOGENETICS; REVIEW; RISK FACTOR; TREATMENT FAILURE; YEAST; DRUG EFFECT; FUNGUS; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; MYCOSES; RISK FACTORS; TREATMENT FAILURE;

EID: 0141524522     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1201-9712(02)90154-2     Document Type: Review

References (37)

1. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662-678.
2. Saag MS, Graybill JR, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30:710-718.
3. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30:696-709
4. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. NCCLS document M27-A. Wayne PA: NCCLS, 1997.
5. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12:501-517.
6. Francis P, Walsh TJ. Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992; 15:1003-1018.
7. Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clin Infect Dis 1998; 27:260-264.
8. White TC, Marr KA, Bowden R. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11:382-402.
9. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39:1-8.
10. Orozco A, Higginbotham L, Hitchcock C, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother 1998; 42:2645-2649.
11. Loffler J, Kelly SL, Hebart H, Schumacher U, LassFlorl C, Einsele H. Molecular analysis of cyp51 from fluconazole resistant Candida albicans strains. FEMS Microbiol Lett 1997; 151:263-268.
12. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14 alpha demethylase (CYP51A1) from azole resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 1998; 42:241-253.
13. Vanden Bossche H, Marichal HP, Odds F, Le Jeune L, Coene M. Characterization of an azole resistant Candida glabrata isolate. Antimicrob Agents Chemother 1992; 36:2602-2610.
14. Joseph-Horne T, Hollomon D, Loeffler RS, Kelly SL. Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother 1995; 39:1526-1529.
15. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39:2378-2386.
16. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from an HIV-infected patient. Antimicrob Agents Chemother 1997; 41:1482-1487.
17. Vanden-Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D. Antifungal drug resistance in pathogenic fungi. Med Mycol 1998; 36(suppl): 1119-1128.
18. Feldmesser M, Kress Y, Mednick A, Casadevall A. The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. J Infect Dis 2000; 182:1791-1795.
19. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167:1247-1251.
20. Pfaller MA, Jones RN, Doern GV, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY program. J Clin Microbiol 1998; 36:1886-1889.
21. Paterson PJ, McWhinney PH, Potter M, Kibbler CC, Prentice HG. The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients. Br J Haematol 2001; 112:175-180.
22. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39:1-8.
23. Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole resistant candidiasis in HIV infected patients. J Infect Dis 1996; 173:219-225.
24. Poynton CH, Barnes RA, Rees J. Interferon gamma and granulocyte- macrophage colony stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin Infect Dis 1998; 26:239-240.
25. Rex JH, Bennett JE, Sugar AM, et al. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis 1995; 21:994-996.
26. Baillie GS, Douglas LJ. Role of dimorphism in the development of Candida albicans biofilms. J Med Microbiol 1999; 48:671-679.
27. Horsburgh CR, Kirkpatrick CH. Long term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with 21 patients. Am J Med 1983; 74(suppl 1b): 23-29.
28. Barchiesi F, Hollis RJ, McGough DA, Scalise G, Rinaldi MG, Pfaller MA. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS. Clin Infect Dis 1995; 20:634-640.
29. Lee SC, Fung CP, Huang JS, et al. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000; 44:2715-2718.
30. Rex JH, Pfaller MA, Barry AL, et al. Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrob Agents Chemother 1995; 39:40-44.
31. Sobel JD, Vazquez JA. Symptomatic vulvovaginitis due to fluconazole resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996; 22:726-727.
32. Hudson MMT. Antifungal resistance and over-the-counter availability in the UK: a current perspective. J Antimicrob Chemother 2001; 48:345-350.
33. Rex JH, Pfaller MA, Walsh TJ, et al Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev 2001; 14:643-658.
34. Powderly WG, Kobayashi GS, Herzig GP, Medoff G. Amphotericin B resistant yeast infections in severely immunocompromised patients. Am J Med 1998; 84:826-832.
35. Witt MD, Lewis RJ, Larsen RA, et al. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing. Clin Infect Dis 1996; 22:322-328.
36. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi. Proposed standard. NCCLS document M38-P. Wayne Pa: NCCLS, 1998.
37. Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41:1264-1368.